The pharmaceutical product sales of AstraZeneca declined by 5% in 2017, to which Onglyza, Symbicort, and Crestor, etc. could be said to have made "big contributions". The main reasons for that were patent expiration, generic drug competition, and drug price pressure, etc. However, according to the 2017 pharmaceutical product sales, the following drugs may bring good income to AstraZeneca in 2018: the oncology and CVMD diseases will be its main directions, wherein, the oncology drugs will account for the highest proportion.

Table 2 Sales of Partial Pharmaceutical Products of AstraZeneca in 2017
|
Pharmaceutical product |
Indication |
2017 |
2017 Q4 |
||
|
Amount (USD 100 million) |
Growth (%) |
Amount (USD 100 million) |
Growth (%) |
||
|
Tagrisso (osimertinib) |
EGFR T790M mutation-positive NSCLC |
9.55 |
126 |
1.07 |
105 |
|
Lynparza (olaparib) |
Ovarian cancer |
2.97 |
36 |
1 |
61 |
|
Imfinzi (durvalumab) |
Urothelium carcinoma |
0.19 |
-- |
0.18 |
-- |
|
Calquence (acalabrutinib) |
Mantle cell lymphoma |
0.03 |
-- |
0.03 |
-- |
|
Brilinta (ticagrelor) |
Anticoagulation |
10.79 |
29 |
2.99 |
27 |
|
Farxiga (dapagliflozin) |
Type 2 diabetes |
10.74 |
29 |
3.32 |
39 |
Also read: AstraZeneca:2018 Sale Directions from 2017 Financial Report and Chinese Market
Tagrisso (osimertinib)—for the treatment of patients with specific epidermal growth factor receptor (EGFR) mutation (T790M)-positive non-small cell lung cancer (NSCLC), whose disease has progressed after EGFR inhibitor therapy. Compared to 2016, the sales increase of Tagrisso was 126% in 2017, reaching USD 955 million, being the best-selling oncology drug of Ast...










(All Rights Reserved)